论文部分内容阅读
目的:观察糖肾丸联合黄葵胶囊治疗糖尿病肾病的临床疗效。方法:选择2014年1月—2015年12月本院收治的糖尿病肾病(DN)患者80例,随机分为治疗组40例和对照组40例。比较两组临床疗效及中医证候疗效,观察两组治疗前后24 h尿蛋白定量、胱抑素C(Cys-C)、尿白蛋白/尿肌酐比值(ACR)。结果:治疗组在西医临床疗效及中医证候改善方面均明显优于对照组,治疗组治疗后24 h尿蛋白定量、Cys-C明显低于治疗前及对照组,差异均有统计学意义(P<0.05)。对照组24 h尿蛋白定量、Cys-C治疗前后比较差异有统计学意义(P<0.05)。对照组ACR治疗前后比较差异有统计学意义(P<0.05)。治疗组治疗后ACR明显低于治疗前及对照组,差异均有统计学意义(P<0.05)。结论:治疗组较对照组能达到更好的临床疗效及临床中医证候改善,降低DN患者24 h尿蛋白排泄、Cys-C及ACR,延缓肾小球硬化的发展,效果明显优于西医对照组。
Objective: To observe the clinical efficacy of Tangshen Pill combined with Huang Kui Capsule in the treatment of diabetic nephropathy. Methods: 80 patients with diabetic nephropathy (DN) treated in our hospital from January 2014 to December 2015 were randomly divided into treatment group (40 cases) and control group (40 cases). The curative effect of TCM and curative effect of traditional Chinese medicine were compared between the two groups. Urine protein, cystatin C (Cys-C), urinary albumin / urinary creatinine ratio (ACR) 24 h before and after treatment were observed. Results: The treatment group was significantly better than the control group in the clinical efficacy of Western medicine and the improvement of TCM syndromes. The urinary protein and Cys-C in 24 h after treatment in the treatment group were significantly lower than those before treatment and in the control group (P < P <0.05). Control group 24 h urinary protein, Cys-C treatment before and after the difference was statistically significant (P <0.05). There was significant difference in ACR before and after treatment in control group (P <0.05). After treatment, the ACR in the treatment group was significantly lower than that before treatment and in the control group (P <0.05). Conclusion: The treatment group than the control group to achieve better clinical efficacy and improvement of clinical TCM syndrome, reduce 24 h urinary protein excretion, Cys-C and ACR, delay the development of glomerulosclerosis in patients with DN, the effect is significantly better than the Western medicine control group.